Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

News | Atrial Fibrillation

Positive Results from ReVeRA Phase 2 Study of Etripamil Nasal Spray in AFib-RVR Presented by Milestone Pharmaceuticals during AHA 2023

November 24, 2023 — During the American Heart Association Scientific Sessions 2023, held recently in Philadephia, PA, Mi ...

November 22, 2023

News | Pharmaceuticals

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

November 21, 2023 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...

November 21, 2023

Zerlasiran showed very significant and durable reductions in lipoprotein(a) of up to 99% Lp(a) levels remained around 90% lower than baseline at study endpoint

News | Cardiovascular Clinical Studies

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

November 10, 2023 — Silence Therapeutics plc, an experienced and innovative biotechnology company committed to ...

November 10, 2023

3-part video series on hypertrophic cardiomyopathy with Christine E. Seidman, MD, FACC, FAHA

Feature | Pharmaceuticals | By Christine Book

Hypertrophic Cardiomyopathy Video Series with Christine E. Seidman, MD, FACC, FAHA

In a new 3-part video series on hypertrophic cardiomyopathy with Christine E. Seidman, MD, FACC, FAHA, Managing Editor ...

October 25, 2023

Videos | Pharmaceuticals

VIDEO, Part 3: Award-winning Researcher Shares Update on Hypertrophic Cardiomyopathy Work and Value of Mentoring

In this third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman, learn what’s on the horizon at ...

September 26, 2023

Videos | Pharmaceuticals

VIDEO, Part 2: Hypertrophic Cardiomyopathy in Focus

In Part 2 of DAIC’s 3-part “One on One” series with Dr. Christine Seidman, a discussion on the discovery of gene-based ...

September 11, 2023

Non-inferiority and safety of one-month DAPT with BIOTRONIK’s drug-eluting stent presented as late-breaker at ESC 2023

News | Cardiovascular Clinical Studies

12-Month-Data of BIOFLOW-DAPT Study Show Positive Results for Orsiro Mission DES With Short DAPT

August 30, 2023 — BIOFLOW-DAPT one-year-data demonstrated non-inferiority and a good safety profile for the Orsiro ...

August 30, 2023

STOPDAPT-3 trial presented in a Hot Line Session Saturday at ESC Congress 2023

News | Antiplatelet and Anticoagulation Therapies

Dual-antiplatelet Therapy Should Remain Standard Strategy After Stent Implantation

August 28, 2023 — Prasugrel monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents is not ...

August 28, 2023

Videos | Pharmaceuticals

VIDEO, Part 1: Hypertrophic Cardiomyopathy: One on One with a Cardiovascular Research Leader

A 3-part video series with Christine E. Seidman, MD, FACC, FAHA

In the first of this 3-part “One on One” series, Dr ...

August 28, 2023

Esperion announced two oral presentations to take place in the Late-Breaking Science Session entitled “Clinical trial updates on prevention and lipid lowering” at the 2023 ESC Congress

News | Cardiovascular Clinical Studies

Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023

August 14, 2023 — Esperion announced two oral presentations to take place in the Late-Breaking Science Session entitled ...

August 14, 2023

Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial

News | Cardiovascular Clinical Studies

Major Adverse Cardiovascular Events Reduced in Overweight/Obese Patients with Wegovy, per SELECT Trial

August 9, 2023 — Novo Nordisk announced the headline results from the SELECT cardiovascular outcomes trial. The double ...

August 09, 2023

LX2020 preclinical studies demonstrated proof-of-concept with treatment restoring desmosomal integrity, reducing arrhythmias, and extending survival in a clinically relevant murine model

News | Pharmaceuticals

LEXEO Therapeutics Announces FDA Clearance of IND for LX2020, an AAV-based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy

August 1, 2023 —LEXEO Therapeutics, a clinical-stage gene therapy company advancing adeno-associated virus (AAV)-based ...

August 01, 2023

Here is a look at what DAIC viewers were reading during the month of July

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

What Viewers Were Reading in July

Here is a look at what DAIC viewers were reading during the month of July:

1. Lessons Learned from World’s First ...

August 01, 2023

New U.S. patent provides intellectual property (IP) protection until December 2040, and may qualify for term extension beyond 2040

News | Hypertension

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

July 26, 2023 — Tenax Therapeutics, Inc, a specialty pharmaceutical company focused on identifying, developing and ...

July 26, 2023

Eli Lilly and Company and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases

News | Cardiovascular Business

Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases

July 14, 2023 — Eli Lilly and Company and Versanis Bio today announced a definitive agreement for Lilly to acquire ...

July 14, 2023